Skip to Main Content

WASHINGTON — Congressman Greg Walden, a key House Republican for pharmaceutical policy, suggested this week that President Trump wants to encourage drug makers to enter value-based contracts with private health plans and the government insurance programs. Maybe that’s what the president has meant all along in his vague promises to change bidding and negotiations.

If that’s true, the drug industry could actually see some federal policy changes it has long sought.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED